ArticleFrontiers in cardiovascular medicine2025
Prognostic value of elevated postoperative high-sensitivity troponin T in diabetes mellitus patients for ischemic events within 12 months after PCI in ACS patients: a retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the prognostic value of high-sensitivity cardiac troponin T (hs-cTnT) levels and diabetes mellitus (DM) on ischemic events within 12 months after percutaneous coronary intervention (PCI) in acute coronary syndrome(ACS) patients. Methods: This retrospective cohort study included 14,173 consecutive ACS patients undergoing PCI at the General Hospital of the Northern Theater Command between March 2016 and March 2022. The primary outcome was the occurrence of ischemic events within 12 months, defined as a composite of cardiac death, non-fatal myocardial infarction (MI), and/or stroke. Secondary outcomes included all-cause mortality at 12 months and the individual components of the primary outcome. Results: During the 12-month follow-up, the overall incidence rates of ischemic events, cardiac death, MI, stroke, and all-cause mortality were 2.19%, 1.12%, 0.58%, 0.59%, and 1.55%, respectively. Elevated hs-cTnT levels were significantly associated with increased risks of ischemic events (adjusted HR: 1.91, 95% CI: 1.19-3.09), cardiac death (adjusted HR: 2.00, 95% CI: 1.08-3.71), and all-cause mortality (adjusted HR: 2.78, 95% CI: 1.62-4.76). In diabetic patients, the risks were particularly pronounced when hs-cTnT levels reached ≥5 × URL. Interaction analyses showed no significant interaction between hs-cTnT levels and diabetes status regarding ischemic events ( Conclusions: Elevated hs-cTnT levels and the presence of DM are independently associated with an increased risks of ischemic events and all-cause mortality after PCI in ACS patients. The impact of hs-cTnT on mortality is more pronounced in diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.